Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Toru Yoshinari
Observed names:
T. Yoshinari,
Toru YOSHINARI,
Yoshinari, Toru
Institution:
Tanabe Pharma Corporation (Japan)
Observed institutions:
Tokyo Medical and Dental University,
Mitsubishi Chemical (Japan),
Keio University,
Tanabe Pharma Corporation (Japan),
NTT Medical Center Sapporo,
Saitama Medical University
show all 6
OpenAlex ID:
A5075196043
Baseline tumour necrosis factor alpha levels predict the necessity for dose escalation of infliximab therapy in patients with rheumatoid arthritis
2011
·
Tsutomu Takeuchi
, Nobuyuki Miyasaka
, et al.
·
Annals of the Rheumatic Diseases
·
160
PDF
Efficacy and safety of canagliflozin in Japanese patients with type 2 diabetes: a randomized, double‐blind, placebo‐controlled, 12‐week study
2013
·
N. Inagaki
, K. Kondo
, et al.
·
Diabetes Obesity and Metabolism
·
145
PDF
Efficacy and safety of canagliflozin monotherapy in Japanese patients with type 2 diabetes inadequately controlled with diet and exercise: a 24-week, randomized, double-blind, placebo-controlled, Phase III study
2014
·
Nobuya Inagaki
, Kazuoki Kondo
, et al.
·
Expert Opinion on Pharmacotherapy
·
133
Golimumab in combination with methotrexate in Japanese patients with active rheumatoid arthritis: results of the GO-FORTH study
2011
·
Yoshiya Tanaka
, Masayoshi Harigai
, et al.
·
Annals of the Rheumatic Diseases
·
119
PDF
Apararenone in patients with diabetic nephropathy: results of a randomized, double-blind, placebo-controlled phase 2 dose–response study and open-label extension study
2020
·
Takashi Wada
, Masaya Inagaki
, et al.
·
Clinical and Experimental Nephrology
·
108
PDF
High titers of both rheumatoid factor and anti-CCP antibodies at baseline in patients with rheumatoid arthritis are associated with increased circulating baseline TNF level, low drug levels, and reduced clinical responses: a post hoc analysis of the RISING study
2017
·
Tsutomu Takeuchi
, Nobuyuki Miyasaka
, et al.
·
Arthritis Research & Therapy
·
82
PDF
Dramatic impact of a Psoriasis Area and Severity Index 90 response on the quality of life in patients with psoriasis: An analysis of Japanese clinical trials of infliximab
2011
·
Hideshi TORII
, Noriko SATO
, et al.
·
The Journal of Dermatology
·
77
Efficacy and safety of canagliflozin alone or as add‐on to other oral antihyperglycemic drugs in Japanese patients with type 2 diabetes: A 52‐week open‐label study
2014
·
Nobuya Inagaki
, Kazuoki Kondo
, et al.
·
Journal of Diabetes Investigation
·
72
PDF
C-reactive protein is an indicator of serum infliximab level in predicting loss of response in patients with Crohn’s disease
2013
·
Toshifumi Hibi
, Atsushi Sakuraba
, et al.
·
Journal of Gastroenterology
·
64
Golimumab monotherapy in Japanese patients with active rheumatoid arthritis despite prior treatment with disease-modifying antirheumatic drugs: results of the phase 2/3, multicentre, randomised, double-blind, placebo-controlled GO-MONO study through 24 weeks
2012
·
Tsutomu Takeuchi
, Masayoshi Harigai
, et al.
·
Annals of the Rheumatic Diseases
·
63
PDF
Pharmacokinetic and Pharmacodynamic Profiles of Canagliflozin in Japanese Patients with Type 2 Diabetes Mellitus and Moderate Renal Impairment
2014
·
Nobuya Inagaki
, Kazuoki Kondo
, et al.
·
Clinical Drug Investigation
·
33
PDF
Inhibition of plasma IL-6 in addition to maintenance of an efficacious trough level of infliximab associated with clinical remission in patients with rheumatoid arthritis: analysis of the RISING Study
2012
·
Tsutomu Takeuchi
, Nobuyuki Miyasaka
, et al.
·
Annals of the Rheumatic Diseases
·
31
Clinical efficacy, radiographic progression, and safety through 156 weeks of therapy with subcutaneous golimumab in combination with methotrexate in Japanese patients with active rheumatoid arthritis despite prior methotrexate therapy: final results of the randomized GO-FORTH trial
2015
·
Yoshiya Tanaka
, Masayoshi Harigai
, et al.
·
Modern Rheumatology
·
16
PDF
A multicenter, open-label, long-term study of three-year infliximab administration in Japanese patients with ankylosing spondylitis
2016
·
Shigeto Kobayashi
, Toru Yoshinari
·
Modern Rheumatology
·
8
Clinical efficacy, radiographic, and safety results of golimumab monotherapy in Japanese patients with active rheumatoid arthritis despite prior therapy with disease-modifying antirheumatic drugs: Final results of the GO-MONO trial through week 120
2017
·
Tsutomu Takeuchi
, Masayoshi Harigai
, et al.
·
Modern Rheumatology
·
7
PDF
Prediction of Clinical Response After 1 Year of Infliximab Therapy in Rheumatoid Arthritis Based on Disease Activity at 3 Months: Posthoc Analysis of the RISING Study
2015
·
Tsutomu Takeuchi
, Nobuyuki Miyasaka
, et al.
·
The Journal of Rheumatology
·
7
PDF
Sa2044 Decrease in Serum Infliximab Level Precedes Loss of Clinical Response and Can Be Easily Detected by the Elevation of C-Reactive Protein in Crohn's Disease
2012
·
Toshifumi Hibi
, Atsushi Sakuraba
, et al.
·
Gastroenterology
·
4
PDF
FRI0176 Golimumab, a human anti-TNF monoclonal antibody, administered subcutaneously every four weeks as monotherapy in patients with active rheumatoid arthritis despite dmard therapy: 52-week results of clinical, radiographic and pharmacokinetic assessments
2012
·
T. Takeuchi
, M. Harigai
, et al.
·
Annals of the Rheumatic Diseases
·
3
OP0229 Both High Titer of RF/ACPA at Baseline Is Closely Linked with High Level of Baseline Plasma TNF Level Which Resulted in Low Drug Level and Low Clinical Response in Infliximab Treatment in RA Patients: Post-Hoc Analysis of A Double-Blind Clinical Study (Rising Study)
2016
·
T. Takeuchi
, N. Miyasaka
, et al.
·
Annals of the Rheumatic Diseases
·
2
FRI0177 52-week results of clinical, radiographic and pharmacokinetic assessments: Golimumab, a human anti-TNF monoclonal antibody, administered subcutaneously every four weeks in patients with active rheumatoid arthritis despite methotrexate therapy
2012
·
Y. Tanaka
, M. Harigai
, et al.
·
Annals of the Rheumatic Diseases
·
2
FRI0197 Golimumab monotherapy in patients with active rheumatoid arthritis despite dmard therapy: week 104 results of clinical, radiographic and safety assessments including evaluation of remission using the new acr/eular criteria
2013
·
T. Takeuchi
, M. Harigai
, et al.
·
Annals of the Rheumatic Diseases
·
1
FRI0205 Golimumab administered subcutaneously every four weeks in patients with active rheumatoid arthritis despite methotrexate therapy: long-term clinical, radiographic and safety results, including evaluation of remission using the new acr/eular criteria
2013
·
Y. Tanaka
, M. Harigai
, et al.
·
Annals of the Rheumatic Diseases
·
1
FRI0200 Achievement of low disease activity (LDA) at 3 months predicts clinical remission (REM) at 1 year of infliximab (IFX) therapy in ra: post-hoc analysis of a randomized double-blind clinical study (rising study)
2013
·
T. Takeuchi
, T. Yano
, et al.
·
Annals of the Rheumatic Diseases
Show more works
View as search
Works count:
34
Citation count:
1,138
H-index:
13
I10-index:
13
Year
Topic
Type